MK-677 (Ibutamoren) Efficacy Reports from Real Users

What the Clinical Data Actually Shows

MK-677 is a non-peptide, orally active ghrelin receptor agonist that stimulates growth hormone (GH) release from the pituitary gland. Unlike injectable GH secretagogues such as sermorelin or CJC-1295, ibutamoren can be taken by mouth, which explains its popularity among self-experimenters.

The Murphy 1998 Landmark Trial

The most frequently cited controlled study is Murphy et al. (1998), published in the Journal of Clinical Endocrinology & Metabolism. In this double-blind, placebo-controlled trial of 187 older adults (ages 65 and older), 25 mg/day of MK-677 for 12 months increased serum IGF-1 levels by approximately 40% in the first group and up to 89% in healthy older adults selected for low baseline IGF-1 [1]. GH pulsatility was restored to patterns resembling those of younger adults. Fat-free mass increased by a mean of 1.1 kg over 12 months compared to placebo, though total body fat did not change significantly.

Sustained GH Pulsatility Without Tachyphylaxis

A key finding across multiple MK-677 studies is that the compound maintains 24-hour GH pulsatile secretion without the rapid desensitization seen with continuous GH-releasing hormone (GHRH) infusion. Nass et al. (2008) confirmed that 25 mg/day of MK-677 sustained IGF-1 elevation for up to 2 years in 65 healthy older adults, with GH secretion profiles mimicking younger cohorts [2]. Fasting glucose did increase modestly (mean +0.3 mmol/L), a finding that appears repeatedly in user reports as well.

What Trials Did Not Show

No published RCT has demonstrated that MK-677 produces the magnitude of muscle gain, fat loss, or anti-aging effects that online communities sometimes attribute to it. The compound was never advanced to FDA approval. Merck discontinued clinical development in the early 2000s after trials in hip-fracture recovery failed to meet primary endpoints [3].

How Users Report Their Results Online

Forum-based user reports are inherently limited by selection bias, recall bias, and the absence of verified dosing. Posters who experience dramatic positive or negative results are more likely to write about them than those who notice little change. With that caveat, patterns across thousands of posts on r/PEDs, r/Peptides, r/Supplements, and bodybuilding forums reveal several consistent themes.

Sleep Quality: The Most Consistent Positive Report

Sleep improvement is the single most frequently cited benefit. Users describe falling asleep faster, experiencing more vivid dreams, and waking up feeling more rested within the first 5 to 10 days. A representative post from r/Peptides: "MK-677 is the best sleep aid I've ever used. I take 12.5 mg about 30 minutes before bed and I'm out within 15 minutes. Dreams are insanely vivid." This aligns with clinical observations: ghrelin-receptor agonism modulates sleep architecture, increasing stage-3 (deep) sleep duration by roughly 20% in polysomnography studies [4].

Recovery and Soft-Tissue Healing

The second most common positive theme involves faster recovery from training and minor injuries. Users in strength-training communities frequently report reduced joint soreness, faster resolution of tendinopathy symptoms, and improved skin and nail quality over 4 to 8 weeks. These reports are consistent with the known role of IGF-1 in collagen synthesis and connective-tissue repair [5].

Body Composition: Modest and Slow

Reports of body composition changes are more variable. The majority of experienced users describe the effect as "subtle" over 8 to 12 weeks: slight improvements in muscle fullness, marginally better nitrogen retention during a caloric surplus, and modest reductions in recovery time between sessions. Few users report dramatic hypertrophy from MK-677 alone. A common sentiment on r/PEDs: "Don't expect steroid-like gains. Think of it more as a recovery and sleep tool that might give you a small edge over time."

Hair and Skin Changes

A smaller but notable subset of users reports improved hair thickness, faster hair growth, and better skin elasticity after 2 to 3 months. GH and IGF-1 play documented roles in dermal collagen deposition and hair follicle cycling [6], so these reports have biological plausibility, though no controlled trial has evaluated MK-677 for dermatological endpoints.

Side Effects Reported by Real Users

Side-effect reports are at least as consistent as efficacy reports, and several effects appear with high frequency.

Appetite Increase

The most universally reported side effect is a pronounced increase in hunger, typically starting within the first 48 hours. MK-677 is a ghrelin mimetic, and ghrelin is the primary orexigenic (hunger-stimulating) hormone. Users describe the appetite surge as "relentless" in the first 2 to 3 weeks, with most reporting that it moderates somewhat after 4 to 6 weeks. Multiple r/PEDs users recommend bedtime dosing specifically to sleep through the worst of the appetite spike.

Water Retention and Bloating

Dose-dependent water retention is the second most common complaint. Users taking 25 mg/day frequently report 2 to 4 kg of water-weight gain within the first 2 weeks, accompanied by puffiness in the face and hands. Users who reduce to 10 to 12.5 mg/day consistently report less edema. The mechanism likely involves GH-mediated sodium and water reabsorption at the renal tubule [7].

Lethargy and Morning Grogginess

Despite improving sleep quality at night, a subset of users (estimated at 20 to 30% based on forum polls, though these polls lack methodological rigor) describe next-day lethargy, brain fog, or difficulty waking up, particularly at doses above 15 mg. This may relate to prolonged GH pulses during the early morning hours or to the sedative properties of ghrelin-receptor activation itself.

Blood Sugar and Insulin Sensitivity

Elevated fasting blood glucose is the most medically significant side effect reported by users who track bloodwork. Forum posters who share lab results commonly show fasting glucose increases of 5 to 15 mg/dL after 4 to 8 weeks on MK-677. This tracks closely with clinical data: Murphy et al. Found a mean fasting glucose increase of approximately 5.4 mg/dL (0.3 mmol/L) at 12 months [1]. Users with prediabetes or insulin resistance report more pronounced glucose elevations, and several posts describe discontinuing MK-677 after HbA1c increases.

Numbness and Tingling

Intermittent paresthesia (tingling in the hands, especially upon waking) appears in roughly 10 to 15% of user reports. GH excess can cause fluid retention in the carpal tunnel, producing symptoms that mimic carpal tunnel syndrome. This side effect generally resolves within days of dose reduction or discontinuation.

Dosing Patterns Users Actually Follow

Clinical trials used 25 mg/day. Online communities have largely settled on a range of 10 to 25 mg/day, with many experienced users preferring 10 to 12.5 mg as a "minimum effective dose" that provides sleep and recovery benefits with fewer side effects.

Timing Preferences

The overwhelming majority of forum users dose MK-677 at bedtime (within 30 to 60 minutes of sleep). This approach serves two purposes: it allows the user to sleep through the peak appetite surge, and it aligns the GH pulse with the natural nocturnal GH peak, potentially amplifying the physiological secretion pattern rather than creating a non-physiological daytime spike.

Cycle Length and Continuity

Opinions diverge on cycle length. Some users run MK-677 continuously for 6 to 12 months, citing the Nass et al. 2-year data as evidence of sustained efficacy [2]. Others cycle 8 weeks on, 4 weeks off, primarily to manage appetite and water retention. No clinical data supports one approach over the other for non-medical use.

Bloodwork Monitoring

The more medically cautious users in r/Peptides and r/PEDs recommend baseline and 8-week blood panels including fasting glucose, fasting insulin, IGF-1, and a comprehensive metabolic panel. Several posts describe meaningful IGF-1 increases (from mid-100s to 300+ ng/mL) on 25 mg/day, confirmed by lab results. This range is broadly consistent with the 40 to 89% increases observed in the Murphy trial [1].

How MK-677 Compares to Injectable GH Secretagogues in User Reports

Users who have tried both MK-677 and injectable peptides (sermorelin, ipamorelin, CJC-1295/ipamorelin combinations) frequently compare them on forums.

Convenience vs. Potency

MK-677's oral bioavailability is its primary advantage. No reconstitution, no syringes, no cold storage. Users who switch from injectable peptides to MK-677 cite convenience as the main reason. Those who switch in the other direction typically cite fewer side effects (less appetite stimulation, less water retention) with ipamorelin-based protocols.

Side Effect Profile Differences

Ipamorelin does not activate the ghrelin receptor, so it produces minimal appetite stimulation and less water retention than MK-677. Multiple comparison posts describe ipamorelin as "cleaner" but requiring daily or twice-daily subcutaneous injection. MK-677 is described as "more convenient but messier" in terms of side effects. The GH/IGF-1 elevation magnitude appears comparable at standard doses, though no head-to-head RCT exists.

Cost Considerations

At research-chemical pricing (the primary channel for non-prescription MK-677), users report spending $30 to $60 per month. Compounded ipamorelin/CJC-1295 from a licensed 503B pharmacy through a telehealth provider typically costs $150 to $300 per month, but comes with medical oversight, verified purity, and a prescription. Several r/Peptides regulars note that the cost difference narrows considerably when factoring in blood work and the risk of receiving under-dosed or contaminated research chemicals.

Limitations of User-Reported Data

Every claim in this article derived from forum posts should be interpreted with the following biases in mind.

Survivorship and Reporting Bias

Users who notice nothing (the likely majority) rarely post. Those with strong positive or negative experiences are overrepresented. Forum efficacy "rates" are not prevalence estimates.

Unverified Sourcing

Most MK-677 purchased through research-chemical vendors is not third-party tested to pharmaceutical standards. Under-dosing, over-dosing, and contamination have been documented in independent analyses of gray-market research chemicals [8]. A user reporting "no effect" may have received an inert product. A user reporting unusual side effects may have received a contaminated one.

Confounders

Forum users rarely control for concurrent supplements, training changes, dietary shifts, or other PEDs. Attributing specific outcomes to MK-677 alone is unreliable in uncontrolled self-reports.

Who Should Avoid MK-677

Based on clinical data and the pattern of user-reported adverse effects, the following groups face elevated risk.

Individuals with Insulin Resistance or Type 2 Diabetes

GH opposes insulin action. MK-677 reliably raises fasting glucose by 5 to 15 mg/dL, and users with prediabetes report larger spikes. The Endocrine Society's 2019 guidelines on GH therapy note that GH-related glucose impairment requires monitoring in all patients, with particular caution in those with existing glucose dysregulation [9].

Those with a History of Pituitary Tumors

GH secretagogues stimulate the pituitary. While no MK-677 trial has reported tumor growth, the theoretical concern is sufficient that clinical investigators have excluded subjects with pituitary pathology from all published trials [1][2].

Adolescents and Those with Open Growth Plates

GH and IGF-1 stimulate epiphyseal growth. Unmonitored GH secretagogue use in individuals with open growth plates could theoretically accelerate or alter bone growth in unpredictable ways.

The Bottom Line on MK-677 Efficacy

Clinical evidence confirms that MK-677 at 25 mg/day raises IGF-1 by 40 to 89% and restores youthful GH pulsatility in older adults over 12 to 24 months [1][2]. Real-user reports align with this data directionally: better sleep, faster recovery, modest lean-mass gains, and predictable side effects (hunger, water retention, glucose elevation). The compound was never FDA-approved, clinical development was abandoned, and online sourcing introduces purity and dosing risks that controlled trials do not face. Fasting glucose should be monitored at baseline and every 8 to 12 weeks in anyone using MK-677, per endocrinology best practices [9].